|
ORF cDNA clones
|
CRISPR / TALEN
|
Lentivirus
|
AAV
|
TALE-TF
|
ORF knockin clones
|
|
Antibody
|
Proteins
|
miRNA target clones
|
qPCR primers
|
shRNA clones
|
miRNA products
|
Promoter clones
|
Validated All-in-One™ qPCR Primer for WT1(NM_024426.6) Search again
Product ID:
HQP162868
(click here to view gene annotation page)
Powered by BiozSpecies:
Human
Symbol:
Alias:
AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1, WT33
Gene Description:
WT1 transcription factor
Target Gene Accession:
NM_024426.6(click here to view gene page)
Estimated Delivery:
Approximately 1-3 weeks, but may vary. Please email sales@genecopoeia.com or call 301-762-0888 to confirm ETA.
Important Note:
By default, qPCR primer pairs are designed to measure the expression level of the splice variant (accession number) you selected for this gene WITHOUT consideration of other possible variants of this gene. If this gene has multiple variants, and you would like to measure the expression levels of one particular variant, multiple variants, or all variants, please contact us for a custom service project at inquiry@genecopoeia.com.
Summary
This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilm's tumors. Multiple transcript variants, resulting from alternative splicing at two coding exons, have been well characterized. There is also evidence for the use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, leading to additional isoforms. Authors of PMID:7926762 also provide evidence that WT1 mRNA undergoes RNA editing in human and rat, and that this process is tissue-restricted and developmentally regulated. [provided by RefSeq].
Gene References into function
- Use of non-AUG (CUG) translation initiation site upstream of, and in-frame with the first AUG, generates longer WT1 isoforms.
- review: role in testis descent
- requirement for Wt1 in normal retina formation with a critical role in Pou4f2-dependent ganglion cell differentiation.
- reduced expression of WT1 causes crescentic glomerulonephritis and mesengial sclerosis and thus a regulator of podocyte function
- Cyclin E is a target of WT1 transcriptional repression
- A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X
- uterine papillary serous carcinomas were nonreactive for WT1
- Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product.
- The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia.
- quantitation of WT1 RNA in Japanese patients with paroxysmal nocturnal hemoglobinuria
- A peptide representing positions 124-148 of the Kruppel-like zinc finger protein was predicted to bind to the HLA-DRB1*0401 molecule. Its sequence is PQQMGSDVRDLNALL.
- WT1 protein contributes to breast cancer progression by promoting breast cancer cell proliferation
- The retinoblastoma-derived human cell line, Y-79, contained robust amounts of Wt1 mRNA and protein. Wt1 expression was down-regulated upon laminin-induced differentiation of Y-79 into neuron-like cells.
- WT1 missense mutations in exon 7, which affect zinc finger 1, alter not only renal function but also male gonadal development in a patient with Denys-Drash syndrome and a 46,XY karyotype.
- abnormal WT1 expression may contribute to the disturbed differentiation of haaematopoietic cells in MDS patients
- CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 were observed in patients with acute myeloid leukemia, and not in controls.
- WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells
- Results suggest that bone marrow zinc finger 2 (BMZF2) interferes with the transactivation potential of Wilms tumor suppressor gene (WT1).
- Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL
- Interacts with p53 in insulin-like growth factor-I receptor gene regulation
- Correlation between a specific Wilms tumour suppressor gene (WT1) mutation and the histological findings in Wilms tumour (WT)
- Alternative splicing, RNA editing, and the use of alternative translation initiation sites generate a multitude of isoforms, which seem to have overlapping but also distinct functions during embryonic development and the maintenance of organ function.
- role in regulating taurine transporter gene
- Epigenetic silencing of WT1 by promoter hypermethylation with loss of heterozygosity is consistent with the revised two-hit model in Wilms' tumorigenesis.
- Overexpression of the Wilms' tumor gene WT1 is associated with head and neck squamous cell carcinoma
- Overexpressed in human bone and soft-tissue sarcomas.
- WT1 is reexpressed in the cirrhotic liver in relation to disease progression and may play a role in the development of hepatic insufficiency in cirrhosis.
- evidence demonstrating that the WT1 gene is involved in the development and differentiation of T-lineage cells
- findings indicate an important role of the wild-type WT1 gene in the tumorigenesis of primary thyroid cancer
- Expression of WT1 protein was detected in 41 (89%) of 46 cases of colonic and rectal adenocarcinoma.
- Wilms' tumor suppressor is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease.
- WT1 gene is novel downstream target for IGF-I action. Reduced levels of WT1 may facilitate IGF-I-stimulated cell cycle progression. Inhibition of WT1 gene expression by IGF-I be significant in cancer initiation and/or progression.
- WT1 was restricted to nucleus of glomerular podocytes.
- These results suggest that WT1 forms a complex with SRY to regulate transcription and that this WT1-SRY interaction is important in testis development.
- WT1 inhibits the transformed phenotype of breast cancer cells and down-regulates the beta-catenin/TCF signaling pathway through destabilization of beta-catenin.
- There is a molecular basis for the strong bias of paternal allele mutations and variable penetrance observed in syndromes with inherited WT1 mutations.
- BASP1 can confer WT1 cosuppressor activity in transfection assays, and elimination of endogenous BASP1 expression augments transcriptional activation by WT1.
- WT1 has a role in suppressing prostate tumor cell growth
- Co-expression of this gene with MDR1 did not significantly influence the complete response rate to induction therapy.
- The transcription factor PEA3 activates the WT1 promoter.
- Cytotoxic T lymphocytes display strong cytotoxic activity against leukemia cells expressing WT1 endogenously but not against WT1(-) human tumor cells.
- WT1 expression in epithelial tumors of the female genital tract may be related to cell differentiation and histologic subtypes of carcinomas, rather than to primary site of origin
- WT1 levels at presentation correlate with several biologic features of leukemia
- mutations in the WT1 have been found to be present in patients with SRNS in association with Wilms' tumor (WT) and urinary or genital malformations, as well as in patients with isolated steroid resistant nephrotic syndrome
- overexpression of WT1 induced a significant increase in the abundance of endogenous c-myc protein in breast cancer cells, consistent with the upregulation of c-myc transcription following WT1 induction.
- WT1 is expressed in appreciable numbers of endometrial cancers.
- WT1/beta-glucuronidase ratio is a prognostic factor for predicting relapse in patients with acute myeloid leukemia and could be included to establish more defined risk groups.
- WT1 vaccination could induce WT1-specific cytotoxic T lymphocytes and result in cancer regression without damage to normal tissues.
- These results may indicate that the W T1 gene plays an important role in tumorigenesis of primary astrocytic tumors.
- Recombinant WT1 protein can bind and activate the 186-bp NPHS1 fragment in a sequence-specific manner. WT1 may be required for regulation of the NPHS1 gene in vivo.
- Mchanism of action of the WT1 suppression domain, and its function in the context of the role of WT1 as a regulator of development.
- WT1 mRNA was overexpressed in all of the 12 esophageal squamous cell carcinomas examined.
- WT1 protein is processed and expressed in the context of HLA class I molecules similarly on both myeloma and lymphoma cells
- Th1-biased cellular immune responses against WT1 protein should be elicited in patients with hematopoietic malignancies.
- WT1 gene is strongly overexpressed in beta-catenin mutant desmoid tumors.
- WT1 mRNA levels were indicative for hematologic relapse (n = 6) versus response in CML patients
- WT1 protein plays a vital role in regulating cell cycle progression and apoptosis in HER2/neu-overexpressing breast cancer cells.
- the WT1 gene may play an important role in the tumorigenesis of glioblastoma, in contrast to medulloblastoma
- No mutations detected in Japanese congenital nephrotic synddrome patients.
- describe WT1-specific and HLA class II-restricted CD4+ T lymphocytes possessing direct cytotoxic activity against leukemia cells
- The WT1 Genes were determined in bone marrow samples of children with de novo B-lineage (n=170) and T-lineage (n=25) acute lymphoblastic leukemia (ALL).
- frequently detected in the cytoplasm of a subset of high-grade non-Hodgkin lymphomas
- Human transgenic Wt1 is not essential for murine hematopoiesis and that there may be significant differences in its role between mouse and man.
- A novel familial WT1 point mutation in the stop codon of exon 10 (1730A/G; X450W) ws found in 3 members of a family with Wilms tumor and nephropathy.
- Data suggest that WT1 protein expression is maintained during angiogenesis and malignant transformation of endothelial cells and can be considered as a new endothelial marker.
- interplay between WT1 and ERalpha in control of IGF-IR gene transcription
- Binding of the transcriptionally competent Wt1(-KTS) isoform to the minimal EPO promoter was demonstrated; this promoter was activated up to 20-fold by transient cotransfection of Wt1(-KTS) in different cell lines.
- Method for the quantification of WT1 transcript by real-time polymerase chain reaction in acute myeloid leukemia and myelodysplastic syndromses.
- Isoforms of WT1 play antiapoptotic roles at some points upstream of the mitochondria in the intrinsic apoptosis pathway.
- Posttransplant recurrence of proteinuria in a case of focal segmental glomerulosclerosis is associated with WT1 mutation
- The WT1 expression seems to be modulated by the presence of cytokines, especially on day 20 of culture.
- WT1 may have a role in very poor survival of patients with osteogenic sarcoma metastasis
- High levels of WT1 expression is associated with childhood acute leukemia
- higher WT1 expression was associated with favorable cytogenetics subtypes and accordingly with better outcome in children with acute myeloid leukemia
- WT1 splice mutations are not rare in females under 18 years with steroid resistance (SRNS). This occurs in absence of a clear renal pathology picture and frequently in absence of phenotype change typical of Frasier syndrome.
- transcriptional activation of the alpha4integrin gene by Wt1(-KTS) might contribute to normal formation of the epicardium and other tissues in the developing embryo
- These findings increase our knowledge of how WT1 exerts its transcriptional regulatory role and suggests that hnRNP-U may be a candidate Wilms' tumour gene at 1q44.
- The WT1 gene encodes a zinc finger transcription factor involved in kidney and gonadal development and, when mutated, in the occurrence of kidney tumor and glomerular diseases.
- WT1 interacts with the novel splicing regulator RNA binding protein RBM4, further, the longer isoform of WT1 is able to inhibit the effect of RBM4 on alternative splicing.
- The induction of apoptosis by arsenic compounds was accompanied by down-regulation of hTERT and wt1 mRNA and protein expression but up-regulation of par-4.
- role of WT1 in different diseases and normal development--review
- dMolecular profiling of CD34(+) cells uncover a limited number of genes such as WT1 with altered expression that are associated with patients' clinical characteristics and may have potential prognostic application.
- WT1 could function to either promote or suppress a transformed phenotype
- 8 mutations were found in WT1 in Wilms tumor patients, mostly in exons 7 and 9, the DNA binding domain. Adverse outcome correlated with these mutations in patients with FLT3-ITD.
- WT1 overexpression did not protect against p53-mediated apoptosis or ionizing radiation induced cell death. WT1 siRNA increased the radiosensitivity of two human glioma cell lines independently of p53.
- Failure of methylation spreading at the WT1 antisense regulatory region early in renal development, followed by imprint erasure, occurs during Wilms' tumourigenesis.
- study suggests mutations in NPHS2 & WT1 are not a cause of uncomplicated steroid sensitive nephrotic syndrome or frequently relapsing & steroid-dependent nephrotic syndrome(FRNS/SDNS)
- These studies of VEGF regulation by WT1 and dysregulation by DDS(R384W) suggest an important role for WT1 in both normal and tumor-related angiogenesis.
- A functional interaction of WT1 and AR might play a role during the development of the male external genitalia.
- distinguish between idiopathic hypereosinophilic syndromes/chronic eosinophilic leukemia and reactive hypereosinophilia based on WT1 transcript amount
- REVIEW of the isoform-specific effects of WT1 on target gene expression and over-representation of certain isoforms in leukaemia
- WT1 is overexpressed in uterine sarcomas. Since increased levels of mRNA determine the biological role, WT1 might contribute to uterine sarcoma tumour biology.
- Survival analysis stratified by FIGO stage performed on cases using a 10% cut-off showed a shorter disease specific survival in patients with a positive WT1 expression in the ovarian tumor tissue.
- WT1 mutation analysis should be routinely done in females with steroid-resistant nephrotic syndrome.
- Bilateral Wilms tumours showed loss of the wild type WT1 allele (loss of heterozygosity (LOH)) and a tumour specific mutation in catenin beta1 (CTNNB1).
- WT1 is a repressor of matrix metalloproteinase-9, regulated by a nitric oxide/soluble guanylate cyclase-dependent pathway in human lung epithelial cells.
- An important early target of progestins that regulates both proliferation and differentiation in breast cancer cells.
- Wilms tumour was not observed in any aniridia case without a WT1 deletion. Of those with WT1 deletions, 77% with submicroscopic deletions (detectable only by high-resolution FISH analysis) had Wilms tumour compared with 42.5% with visible deletions.
- There was a significantly lower level of WT-1 expression in parathyroid tumours than in normal parathyroid glands. Abnormal expression of WT-1 and the IGF axis may play a role in the pathogenesis of hyperparathyroidism.
- These results show that the expression of the NDRG2 gene is directly or indirectly induced by WT1, and provide the first insights into transcriptional regulation of the NDRG2 gene, including demonstration of a novel splice variant.
- Data report the structure determination by both X-ray crystallography and NMR spectroscopy of the WT1 zinc finger domain in complex with DNA.
- WT1 is useful for the distinction of ovarian Sertoli cell tumor from endometrioid tumors and carcinoids.
- WT1 expression is induced by oncogenic signalling from BCR/ABL1. WT1 contributes to resistance against apoptosis induced by imatinib.
- There was no significant difference in WT1 message between aplastic anemia and refractory anemia, suggesting that WT1 message is not a good tool to discriminate these two diseases.
- report on eight new cases of this condition, two of whom were shown to have heterozygous missense mutations in the C-terminal zinc finger domains of WT1: Arg366Cys and Arg394Trp
- We conclude that WT1 might be an important component of the NO-dependent regulation of T lymphocyte proliferation and potential function.
- Tumors that contained wild-type p53 were significantly more likely to express WT1, and presence of WT1 in glioma support that WT1 expression is important in glioma biology.
- direct role of WT1 in melanoma proliferation, which might be mediated via Nestin and Zyxin
- NPHS2 and WT1 are now known to be genes commonly involved in the pathogenesis of sporadic steroid-resistant nephrotic syndrome. However, the incidence of NPHS2 gene mutation shows interethnic difference.
- WT1 encodes conserved antisense RNAs that may have an important regulatory role in WT1 expression via RNA:RNA interactions, and which can become deregulated by a variety of mechanisms in cancer.
- enhanced tetramer binding of modified WT1-T-Cell Receptor variants was not associated with improved WT1-specific T cell function
- WT1 downregulation during myeloid differentiation of NB4 and HL60 leukemic cell lines is associated with increased tumor repressor hDMP1 mRNA levels
- Pure curcumin decreased WT1 gene expression in both transcriptional and translational levels.
- Nuclear WT1 expression is present in a minority of invasive micropapillary carcinomas and, when present, expression is focal
- This study provides further insight into the mechanisms of transcriptional regulation of the WT1 gene and WT1-associated diseases treatment.
- In pleural malignant effusion, malignant mesothelioma can be identified with positive staining for WT-1 and negative staining for p63.
- Mutations in two other genes WT1 and LAMB2 may also cause IDMS.
- Bone marrow WT1 gene expression analysis is informative only in cases where a more sensitive minimal residual disease (MRD) marker is not available.
- Relapse was observed in eight of 17 patients with acute myelogenous leukemia analysed longitudinally, and an increase of WT1 gene expression preceded morphologic relapse in four patients.
- The researchers found that the Wilms tumor gene 1 is very important in the survival of the breast cancer MCF-7 cell line.
- the -KTS-containing variants of WT1 are directly involved in the regulation of p21(Waf1/Cip1) expression and the subsequent suppression of lymph node metastasis in human lung squamous cell carcinoma
- transcriptional activation of ETS-1 by the Wilms' tumour suppressor WT1 is a crucial step in tumour vascularization via regulation of endothelial cell proliferation and migration.
- WT1 induction led to strong induction of IFI16 expression and its promoter activity was responsive to the WT1 protein.
- WT1 expression in newly diagnosed and relapsed ALL patients was significantly higher than that of the ALL patients at remission and normal subjects
- The expression of WT1 is increased more in HCC than in non-tumour tissues. Overexpressed WT1 was associated with tumour growth, and resulted in a worsening prognosis of HCC. WT1 overexpression might contribute to oncogenic potential.
- Upregulation of Wilms tumor gene protein 1 is associated with ovarian cancer metastasis and modulates cell invasion
- Critical levels of WT1 + KTS, SRY and SOX9 are required for normal Sertoli cell maturation, and subsequent normal spermatogenesis.
- Biallelic loss (the novel germline mutation c.895-2A > G & one LOH in the tumor) of the WT1 gene was associated with drug-resistant bilateral Wilms tumor.
- WT1-shRNA targeting exon 5 should serve as a potent anti-cancer agent for various types of solid tumors.
- WT1 and WTX mutations occur with similar frequency, that they partially overlap in Wilms tumors, and that mutations in WT1, WTX, and CTNNB1 underlie the genetic basis of about one-third of Wilms tumors
- WT1 expression in astrocytes indicates a neoplastic origin and might represent an important diagnostic tool to differentiate reactive from neoplastic astrocytes by immunohistochemistry.
- Recent advances including the development of transgenic mouse models and conditionally immortalized podocyte cell lines are beginning to shed light on WT1's crucial role in podocyte function[review]
- activation of the EpoR gene by Wt1 may represent an important mechanism in normal hematopoiesis
- WT1 is a fairly specific marker for spindle cell tumors of gynecologic organs, including ovarian spindle cell tumors, endometrial stromal tumors, and uterine smooth muscle tumors. Non-GYN spindle cell sarcomas rarely express WT1.
- WT1 may have a role in relapse of acute myeloid leukemia
- three WT1 subtypes were correlated with WT1, IGF2, and CTNNB1 genetics
- study shows that WT1 is expressed de novo in numerous neuroepithelial tumours and increases with the grade of malignancy; results suggest an important role of WT1 in tumourigenesis and progression in brain tumours
- None of the breast carcinoma subtype unassociated with mucinous component showed WT1 expression.
- A novel Wilms' tumor 1 gene mutation in a child with severe renal dysfunction and persistent renal blastema.
- Overexpressed in gastrointestinal stromal tumor and some smooth muscle tumors.
- The presence of WT1 mutations at diagnosis of acute myeloid leukemia is associated with extremely poor outcome, higher risk of relapse and death.
- The expression levels of WT1 and NPM1 in 93 paired samples showed a strong positive correlation. WT1 decreased rapidly after induction but maintained these residual levels after treatment in patients in complete remission.
- WT1 mutations are a negative prognostic indicator in normal karyotype AML and may be suitable for the development of targeted therapy
- expression of ROR1 and WT1 in B-ALL is associated with the differentiation stage of the leukemic cells
- WT1 transactivates another important negative regulator of the Ras/MAPK pathway, MAPK phosphatase 3 (MKP3).
- Maternal transmission of a mutation in exon 1 of the WT1 gene caused genitourinary anomalies.
- Herein, we describe a desmoplastic small round cell tumor of soft tissue with an unusual pattern of WT1 expression associated with a novel variant EWS-WT1 fusion transcript.
- This study clearly implicates WT1 as a mediator of antiestrogen resistance in breast cancer through down-regulation of ERalpha expression.
- WT1 plays an important role in maintaining normal growth of mammary epithelial cells and dysregulated WT1 expression may contribute to breast cancer development.
- Nuclear WT1 expression is present in a minority of endometrioid ovarian carcinomas
- observation that TIA-1 and WT1 are both involved in apoptosis supports our proposal for a functional link between these proteins
- cases with increase of WT1 levels after hematopoietic stem cell transplant and without graft vs. host disease may be candidate to discontinuation of immunosuppression and/or donor lymphocyte infusion therapy
- Although WT1 is expressed in a majority of endometrial carcinomas, a heterogeneous staining pattern is observed.
- quantified both WT1 and PRAME transcript levels in the bone marrow of AML patients. Dynamic patterns of WT1 and PRAME during follow-up showed that a consistent elevation or a rise over time to exceed the normal range predicted clinical relapse
- Expression of the WT1 gene product was found in all tumor samples but no statistically significant correlations between WT1 expression and histologic type
- These results indicate WT1 protein-derived 16-mer natural peptide, WT1(332) (KRYFKLSHLQMHSRKH) is a promiscuous WT1-specific helper epitope.
- Mutations in WT1 gene is associated with Wilms tumor.
- WT1 gene is expressed in a substantial proportion of hepatocellular carcinoma cell lines contributing, to tumor progression and resistance to chemotherapy.